The Operation and Clinical Assessment Core will be responsible for integrating the CIDAR scientific and infrastructure aims. Dr. Carpenter (the P.I.) and the proposed Steering Committee will have overall responsibility for the CIDAR administrative functions. The Steering Committee will include the key scientific leadership for this application: Dr. Koenig (P.I.: Pre-clinical Studies Core and Project #1);Dr. Thaker (P.I.: Research Methods Core and Project #2);Drs. Conley and Buchanan (P.I./Co-P.I.: Project #3);Dr. McMahon (Biostatistician;Co-P.I.: Research Methods Core);and Dr. Gold (Neuropsychologist;Co-P.I.;Research Methods Core). The Steering Committee will formally review the Operation and Clinical Assessment Core, Research Methods Core, and Pre-Clinical Studies Core and research project activities every six months. The Steering Committee will also be responsible for facilitating the involvement of post-doctoral research fellows and junior faculty in CIDAR activities. In consultation with NIMH program staff, the Core will establish an External Advisory Committee and meet with the advisors at the outset to review plans. The External Advisory Committee will include experts in drug discovery and development from academic and industry labs, experts in special assessments relevant to this application, and an expert in biostatistics. The Clinical Assessment component of the Core will be comprised of a: 1) Biostatistics and Data Management Unit (BDM), which will be directed by Robert McMahon, Ph.D. and will provide services in statistical consulting and database management;and 2) Clinical Assessment Unit, which will be directed by Robert W. Buchanan, M.D. The Clinical Assessment Unit will provide: a) reliable and valid diagnostic procedures;b) reliable and valid instruments for assessing symptoms, cognitive function, and social and occupational function;c) training in the use of these instruments, and ongoing intra- and inter-program reliability sessions to maximize consistency in ratings and to control for rater drift;and d) subject recruitment services.

National Institute of Health (NIH)
National Institute of Mental Health (NIMH)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZMH1-ERB-L)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Maryland Baltimore
United States
Zip Code
Buchanan, Robert W; Kelly, Deanna L; Weiner, Elaine et al. (2017) A Randomized Clinical Trial of Oxytocin or Galantamine for the Treatment of Negative Symptoms and Cognitive Impairments in People With Schizophrenia. J Clin Psychopharmacol 37:394-400
Cohen, Alex S; Mitchell, Kyle R; Strauss, Gregory P et al. (2017) The effects of oxytocin and galantamine on objectively-defined vocal and facial expression: Data from the CIDAR study. Schizophr Res 188:141-143
Lee, Mary R; Wehring, Heidi J; McMahon, Robert P et al. (2016) Relationship of plasma oxytocin levels to baseline symptoms and symptom changes during three weeks of daily oxytocin administration in people with schizophrenia. Schizophr Res 172:165-8
Strauss, Gregory P; Keller, William R; Koenig, James I et al. (2015) Endogenous oxytocin levels are associated with the perception of emotion in dynamic body expressions in schizophrenia. Schizophr Res 162:52-6
Strauss, Gregory P; Keller, William R; Koenig, James I et al. (2015) Plasma oxytocin levels predict olfactory identification and negative symptoms in individuals with schizophrenia. Schizophr Res 162:57-61
Strauss, Gregory P; Keller, William R; Koenig, James I et al. (2015) Plasma oxytocin levels predict social cue recognition in individuals with schizophrenia. Schizophr Res 162:47-51
Wilson, Christina A; Koenig, James I (2014) Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia. Eur Neuropsychopharmacol 24:759-73
Schulz, Kalynn M; Andrud, Kristin M; Burke, Maria B et al. (2013) The effects of prenatal stress on alpha4 beta2 and alpha7 hippocampal nicotinic acetylcholine receptor levels in adult offspring. Dev Neurobiol 73:806-14
Braff, David L; Ryan, James; Rissling, Anthony J et al. (2013) Lack of use in the literature from the last 20 years supports dropping traditional schizophrenia subtypes from DSM-5 and ICD-11. Schizophr Bull 39:751-3
Taylor, S B; Taylor, A R; Koenig, J I (2013) The interaction of disrupted type II neuregulin 1 and chronic adolescent stress on adult anxiety- and fear-related behaviors. Neuroscience 249:31-42

Showing the most recent 10 out of 21 publications